To reduce OC risk, BRCA1/BRCA2 pathogenic variant carriers can undergo risk-reducing salpingo-oophorectomy (RRSO).12,13 To reduce BC risk, BRCA1/BRCA2/PALB2 pathogenic variant carriers can be offered enhanced magnetic resonance imaging and mammography screening,14,15 risk-reducing mastectomy (RRM),16 or chemoprevention with selective estrogen receptor modulators.17 This evidence concerns the gene BRCA2 and breast cancer.